Top Growth Stocks To Follow Today – February 10th

SpringWorks Therapeutics, Novo Nordisk A/S, BlackRock, Blackstone, and Incyte are the five Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of companies that are expected to grow at a faster rate than the average for the market or industry. These companies often reinvest earnings into expansion, research and development, or other initiatives to help drive future growth and increase their market value. Growth stocks typically do not pay dividends, as they prioritize using profits for further growth opportunities. These companies had the highest dollar trading volume of any Growth stocks within the last several days.

SpringWorks Therapeutics (SWTX)

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.

SWTX stock traded up $16.30 during trading hours on Monday, reaching $56.58. 9,665,716 shares of the stock were exchanged, compared to its average volume of 2,054,393. The firm’s 50-day moving average is $37.86 and its 200-day moving average is $36.16. The company has a market cap of $4.21 billion, a price-to-earnings ratio of -14.46 and a beta of 0.81. SpringWorks Therapeutics has a 12 month low of $28.21 and a 12 month high of $56.34.

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Shares of Novo Nordisk A/S stock traded down $2.30 during trading hours on Monday, reaching $84.12. 5,010,783 shares of the company’s stock were exchanged, compared to its average volume of 9,354,341. The company has a 50 day moving average of $91.46 and a two-hundred day moving average of $111.21. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. The stock has a market cap of $377.50 billion, a P/E ratio of 25.62, a P/E/G ratio of 0.96 and a beta of 0.45.

BlackRock (BLK)

BlackRock, Inc. is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors including corporate, public, union, and industry pension plans, insurance companies, third-party mutual funds, endowments, public institutions, governments, foundations, charities, sovereign wealth funds, corporations, official institutions, and banks.

NYSE:BLK traded down $6.03 during mid-day trading on Monday, hitting $986.01. The stock had a trading volume of 321,535 shares, compared to its average volume of 801,806. BlackRock has a twelve month low of $745.55 and a twelve month high of $1,084.22. The stock has a market cap of $152.71 billion, a price-to-earnings ratio of 23.46, a PEG ratio of 1.93 and a beta of 1.28. The company’s 50 day simple moving average is $1,024.93 and its 200 day simple moving average is $969.98. The company has a debt-to-equity ratio of 0.45, a quick ratio of 5.23 and a current ratio of 5.23.

Blackstone (BX)

Blackstone Inc. is an alternative asset management firm specializing in real estate, private equity, hedge fund solutions, credit, secondary funds of funds, public debt and equity and multi-asset class strategies. The firm typically invests in early-stage companies. It also provide capital markets services.

BX stock traded down $0.07 during mid-day trading on Monday, hitting $168.76. 1,213,039 shares of the company were exchanged, compared to its average volume of 3,071,736. Blackstone has a 1-year low of $115.82 and a 1-year high of $200.96. The stock has a market capitalization of $121.84 billion, a PE ratio of 46.42, a price-to-earnings-growth ratio of 1.13 and a beta of 1.53. The business has a 50 day simple moving average of $178.36 and a 200-day simple moving average of $163.80. The company has a current ratio of 0.67, a quick ratio of 0.71 and a debt-to-equity ratio of 0.61.

Incyte (INCY)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

Shares of NASDAQ INCY traded down $4.95 during midday trading on Monday, reaching $69.19. The company’s stock had a trading volume of 1,897,561 shares, compared to its average volume of 1,438,602. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.82 and a current ratio of 1.87. Incyte has a fifty-two week low of $50.35 and a fifty-two week high of $83.95. The business’s 50 day moving average price is $71.79 and its two-hundred day moving average price is $69.18. The company has a market cap of $13.33 billion, a P/E ratio of 494.20, a P/E/G ratio of 0.53 and a beta of 0.70.